Skip to main content
. Author manuscript; available in PMC: 2025 Aug 25.
Published in final edited form as: Nat Methods. 2024 Nov 8;22(1):24–40. doi: 10.1038/s41592-024-02480-7

Figure 4.

Figure 4.

Methods of assessing hiPSC-CM functionality and maturation. a. Number of publications that reported analysis of the structure, contraction, gene expression, calcium handling, electrophysiology, and metabolism of hiPSC-CMs. b. Top methods of obtaining each of the reported metrics in a. c. Top genes that were reported in the assessment of hiPSC-CM maturation. d. Top pharmaceutical drugs used to test the ability of hiPSC-CMs to respond as known clinically. e. Proportion of publications that used hiPSC-CM platforms to model disease. f. Top diseases modeled by hiPSC-CM platforms including arrhythmogenic cardiomyopathy (ACM), hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), myocardial infarction (MI), and long QT syndrome (LQT).